Stock listing
Allogene Therapeutics, Inc.
Selected listing: ALLO · NASDAQ · USD · US
Allogene Therapeutics, Inc. (NASDAQ:ALLO), Health Technology. Latest release Sep 2, 2026: Allogene Therapeutics Announces Retirement of Chief Financial…
- Ticker
- NASDAQ:ALLO
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a public biotechnology company based in the United States, focused on developing innovative therapies for cancer treatment. Allogene is dedicated to advancing its research and development efforts in the field of allogeneic cell therapy.
Latest news from Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
September 2, 2026
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 4, 2026
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
July 15, 2026
Events
Research Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. company profile
View the public company page for Allogene Therapeutics, Inc. on 6ix.
Allogene Therapeutics, Inc. news
Read company news and market updates connected to Allogene Therapeutics, Inc..
Allogene Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Allogene Therapeutics, Inc..